An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas


To provide access to selumetinib to people with neurofibromatosis type 1 (NF1) with plexiform neurofibromas that cannot be operated on.


Patients ≥ 2 years old with disease before the age of 18 years old

Diagnosis of neurofibromatosis type 1 (NF1)

Plexiform neurofibromas that cannot be surgically completely removed


There is no maximum duration for this study as long as it is deemed that a response is being obtained.

Interested in more information? Contact Us:

Hematology Oncology Associates

IRB: Quorum
IRB Number:
Trial Type: NA
Sponsor: Astra Zenca